Danish committee does not recommend reimbursement for Novo Nordisk's Wegovy

The Danish pharmaceutical firm’s obesity drug is too expensive, says the Danish Reimbursement committee according to a domestic media.

Photo: Novo Nordisk / PR

The price for Novo Nordisk’s new obesity drug, Wegovy, is not equal to its therapeutic effect, assesses the Danish Reimbursement Committee, which advises the Danish Medicines Agency.

The committee is therefore recommending to the agency that Novo Nordisk’s reimbursement application for Wegovy be rejected, according to Danish media Berlingske.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs